Johnson & Johnson Announces Results From A Subgroup Analysis Of The Phase 3 CARTITUDE-4 Study Showing CARVYKTI Improved Progression-Free Survival And Deepened Responses Versus Two Standard Therapies For Patients With Functional High-Risk Multiple Myeloma
Portfolio Pulse from Benzinga Newsdesk
Johnson & Johnson announced results from a subgroup analysis of the Phase 3 CARTITUDE-4 study, showing that CARVYKTI® significantly improved progression-free survival for patients with high-risk multiple myeloma. The study supported the recent FDA approval of CARVYKTI®.
June 03, 2024 | 7:58 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Johnson & Johnson's CARVYKTI® demonstrated a 73% reduction in the risk of disease progression or death in high-risk multiple myeloma patients, supporting its recent FDA approval.
The positive results from the CARTITUDE-4 study and the recent FDA approval of CARVYKTI® are likely to boost investor confidence in Johnson & Johnson, potentially driving the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100